这一制度使得创新有利可图，从而确实为某些类型的研究提供了激励；但制药公司也因此得以坐地起价，它们获得的激励与社会回报不一定相容。
While this system does provide incentives for certain kinds of research by making innovation profitable, it allows drug companies to drive up prices, and the incentives do not necessarily correspond to social returns.